• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Yang Jianyu

    3/18/26 10:51:54 AM ET
    $CCM
    Medical/Nursing Services
    Health Care
    Get the next $CCM alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Yang Jianyu

    (Last)(First)(Middle)
    SEE REMARKS

    (Street)
    BEIJING100020

    (City)(State)(Zip)

    CHINA

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    Concord Medical Services Holdings Ltd [ CCM ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Executive Officer
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    American depositary shares466,097IBy Morgancreek Investment Holding Limited(1)(4)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Class B ordinary shares, par value US$0.0001 per share (3) (3)Class A ordinary shares, par value US$0.0001 per share38,287,948(3)IBy Morgancreek Investment Holding Limited(2)(4)
    Explanation of Responses:
    1. Represented 466,097 American depositary shares ("ADSs"), each representing 30 Class A ordinary shares, par value US$0.0001 per share, of the Issuer (the "Class A Ordinary Shares") held by Morgancreek Investment Holding Limited ("Morgancreek"), a limited liability company organized under the laws of the British Virgin Islands.
    2. Represented 38,287,948 Class B ordinary shares, par value US$0.0001 per share, of the Issuer ("Class B Ordinary Shares), held by Morgancreek.
    3. The Class B Ordinary Shares are convertible at any time at the option of the holder into an equal number of Class A Ordinary Shares at no cost.
    4. The Reporting Person is the sole director of Morgancreek and the Reporting Person's spouse indirectly holds 70% of the equity interests in Morgancreek. As such the Reporting Person has the power to direct Morgancreek as to the voting and disposition of the Class B Ordinary Shares and the ADSs held by Morgancreek. The Reporting Person may be deemed the beneficial owner of all the Class B Ordinary Shares and ADSs representing Class A Ordinary Shares held by Morgancreek.
    Remarks:
    The full street address is Room A1-A5 26/F, East Zone, Hanwei Plaza, No. 7 Guanghua Road, Chaoyang District. Exhibit 24 - Power of Attorney
    /s/ Jianyu Yang03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $CCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CCM
    SEC Filings

    View All

    SEC Form 6-K filed by Concord Medical Services Holdings Limited

    6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)

    12/2/25 7:18:17 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by Concord Medical Services Holdings Limited

    6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)

    9/30/25 6:02:41 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by Concord Medical Services Holdings Limited

    6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)

    9/26/25 7:35:08 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $CCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Yang Jianyu

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:54 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by Concord Medical Services Holdings Limited

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:33 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by Concord Medical Services Holdings Limited

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:12 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $CCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Concord Medical Schedules 2025 Annual Meeting of Shareholders

    BEIJING, Dec. 2, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it will hold its 2025 annual general meeting of shareholders (the "Meeting") on December 29, 2025, at 10:00 a.m. (Beijing Time). The meeting will be held at Room 26A1-26A5, East Tower, Hanwei Building, No. 7 Guanghua Road, Chaoyang District, Beijing, China. The shareholder record date is December 19, 2025. A copy of the notice of Meeting is available on the Company's investor relations website at https://ir.ccm.cn.  No proposal will be submitted

    12/2/25 7:00:00 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    Concord Medical Reports Financial Results for the First Half of 2025

    BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1]. 2025 First Half Highlights Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network

    9/26/25 7:30:00 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma

    BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma. Choroidal malignant melanoma is a common intraocular malignancy. The traditional standard treatment is enucleation, i.e. eye removal. Although enucleation can effect

    7/14/25 4:05:00 PM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $CCM
    Leadership Updates

    Live Leadership Updates

    View All

    Concord Medical Announces Divestment of Singapore Concord International Hospital

    BEIJING, Dec. 28, 2020 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that the Company has, through its subsidiaries, entered into a definitive agreement to sell 90% equity interest in Concord Healthcare Singapore Pte Ltd, which operates and owns a general medical and surgical hospital, namely Concord International Hospital ("CIH"), for a total consideration of approximately SG$52.2 million. The p

    12/28/20 6:47:00 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $CCM
    Financials

    Live finance-specific insights

    View All

    Concord Medical Reports Financial Results for the First Half of 2025

    BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1]. 2025 First Half Highlights Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network

    9/26/25 7:30:00 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    Concord Medical Reports Financial Results for the First Half of 2024

    BEIJING, Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2024[1]. 2024 First Half Highlights Total net revenues were RMB218.8 million (US$30.1 million) in the first half of 2024, representing a 23.1% decrease from total net revenues of RMB284.5 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB137.8 million (US$19.0 million) and the net revenues from the network

    9/27/24 7:00:00 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    Concord Medical Reports Financial Results for the First Half of 2023

    BEIJING, Sept. 22, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2023[1]. 2023 First Half Highlights Total net revenues were RMB284.5 million (US$39.2 million) in the first half of 2023, representing a 97.2% increase from total net revenues of RMB144.3 million in the same period last year. Total net rev

    9/22/23 5:00:00 PM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $CCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Concord Medical Services Holdings Ltd (0001472072) (Subject)

    2/16/21 7:12:46 AM ET
    $CCM
    Medical/Nursing Services
    Health Care